Building a Credible Healthcare Business from Research IP

The Opening

It began as a university radiation oncology project: software designed to reduce errors during cancer treatment. The patient-safety problem was real, and new treatment-quality standards were increasing the need for this kind of capability.

The opening was real. But a good idea, a serious problem, and good timing were not enough to make a business.

The Real Problem

The first risk was mistaking a validated problem for a validated business.

The tool worked in research, but it was not yet something providers would easily adopt. It sat outside the systems and workflows they already used, and it asked busy clinical institutions to run something separate.

There was also a market-access problem. I was entering a closed clinical market with no brand, no track record, and no inherited relationships. Selling harder would not solve either issue. The product had to become adoptable, and the company had to find a credible way in.

The Build

The product had to be rebuilt to fit the provider’s world.

The university relationship became the first source of credibility: the university received the finished product for its own use, the company retained commercial rights through a revenue-share structure, and key stakeholders helped open doors that a cold approach could not.

The first major customer was a federal healthcare unit. That mattered because it became more than a sale; it became proof that the product could operate in a demanding clinical environment. Services became a second recurring income line, alongside the software product.

The Step Many Ventures Do Not Reach

The final step was reducing founder dependency.

Deployment, qualification, onboarding, and support were turned into a repeatable operating playbook. Customer relationships were moved beyond the founder and into the company, the team, and champions inside each account.

That mattered because a business is not truly transferable while every critical function still runs through the founder. The company later transitioned to a new CEO without customer loss.

The Takeaways I Give Founders

• A validated problem is not the same as a validated business.
• In a closed market, credibility comes before scale. Borrow it if you cannot build it yet.
• When adoption stalls, look at the product and workflow before blaming the pitch.
• If every customer depends on the founder personally, the business has not yet become repeatable.
• Commercial maturity is not only revenue. It is whether the business can run without the founder carrying every critical function.